Showing 1 posts of 1 posts found.
Juno Therapeutics (NASDAQ: JUNO) has announced the acquisition of RedoxTherapies, adding its lead cancer drug candidate, vipadenant, to its portfolio.
MHRA awards Innovation Passports to liver cancer and dementia medicines
Scottish NHS hospital adopts light-activated therapy to reduce surgical infections
Manchester launches nurse-led clinic to improve kidney transplant outcomes
Androlabs and Majorelle expand testosterone therapy into France
Promatix secures Innovate UK funding to advance bispecific ADC programme